Restricted accessResearch articleFirst published online 2019-10
Association Between γ-Glutamyltransferase Level and Cardiovascular or All-Cause Mortality in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis
This meta-analysis assessed the prognostic value of serum γ-glutamyltransferase (GGT) level for cardiovascular (CV) and all-cause mortality in patients with coronary artery disease (CAD). We conducted a systematic literature search of PubMed, Web of Science, Embase, China National Knowledge Infrastructure, Wanfang, and Weipu databases until December 2018. Observational studies investigating the prognostic role of serum GGT level for CV and all-cause mortality in patients with CAD were included. Pooled risk ratios (RR) with 95% confidence intervals (CI) for the highest versus the lowest GGT level were used to summarize the prognostic value. Twelve studies involving 12 531 patients with CAD were included. Meta-analysis showed that elevated GGT level was significantly associated with higher risk of CV mortality (RR: 2.04; 95% CI: 1.57-2.64) and all-cause mortality (RR: 1.49; 95% CI: 1.27-1.74) in patients with CAD. This meta-analysis suggests that elevated serum GGT levels are an independent predictor of CV and all-cause mortality in patients with CAD. Determination of GGT level may improve the prediction of CV and all-cause mortality in patients with CAD.
BenjaminEJBlahaMJChiuveSE, et al.Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135:e146–603.
2.
SchieleFEcarnotFChopardR. Coronary artery disease: risk stratification and patient selection for more aggressive secondary prevention. Eur J Prev Cardiol. 2017;24:88–100.
3.
OrlowskiMMeisterA. The gamma-glutamyl cycle: a possible transport system for amino acids. Proc Natl Acad Sci U S A. 1970;67:1248–55.
4.
TargherG. Elevated serum gamma-glutamyltransferase activity is associated with increased risk of mortality, incident type 2 diabetes, cardiovascular events, chronic kidney disease and cancer—a narrative review. Clin Chem Lab Med. 2010;48:147–57.
5.
NdrepepaGKastratiA. Gamma-glutamyl transferase and cardiovascular disease. Ann Transl Med. 2016;4:481.
6.
WannametheeGEbrahimSShaperAG. Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol. 1995;142:699–708.
7.
BreitlingLPGrandiNCHahmannHWustenBRothenbacherDBrennerH. Gamma-glutamyltransferase and prognosis in patients with stable coronary heart disease followed over 8 years. Atherosclerosis. 2010;210:649–55.
8.
AksakalETanbogaIHKurtM, et al.The relation of serum gamma-glutamyl transferase levels with coronary lesion complexity and long-term outcome in patients with stable coronary artery disease. Atherosclerosis. 2012;221:596–601.
9.
DuGSongZZhangQ. Gamma-glutamyltransferase is associated with cardiovascular and all-cause mortality: a meta-analysis of prospective cohort studies. Prev Med. 2013;57:31–7.
10.
LongYZengFShiJTianHChenT. Gamma-glutamyltransferase predicts increased risk of mortality: a systematic review and meta-analysis of prospective observational studies. Free Radic Res. 2014;48:716–28.
11.
MoherDLiberatiATetzlaffJAltmanDG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9.
BeggCBMazumdarM. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.
14.
EggerMDavey SmithGSchneiderMMinderC. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
15.
KarlsonBWLindqvistJSjolinMCaidahlKHerlitzJ. Which factors determine the long-term outcome among patients with a very small or unconfirmed AMI. Int J Cardiol. 2001;78:265–75.
16.
EmdinMPassinoCMichelassiC, et al.Prognostic value of serum gamma-glutamyl transferase activity after myocardial infarction. Eur Heart J. 2001;22:1802–7.
17.
EmdinMPassinoCMichelassiCDonatoLPompellaAPaolicchiA. Additive prognostic value of gamma-glutamyltransferase in coronary artery disease. Int J Cardiol. 2009;136:80–5.
18.
StojakovicTScharnaglHTraunerM, et al.Serum gamma-glutamyl transferase and mortality in persons undergoing coronary angiography-the Ludwigshafen risk and cardiovascular health study. Atherosclerosis. 2010;208:564–71.
19.
BodeEWuppingerTBodeT, et al.Risk stratification in stable coronary artery disease: superiority of N-terminal pro B-type natriuretic peptide over high-sensitivity C-reactive protein, gamma-glutamyl transferase, and traditional risk factors. Coron Artery Dis. 2012;23:91–7.
20.
OzcanFKarakasMFOzluMF, et al.Effect of serum gamma-glutamyl transferase levels on myocardial perfusion and long-term prognosis after primary angioplasty in patients with acute ST-elevation myocardial infarction. J Investig Med. 2012;60:1186–93.
21.
GulMUyarelHErgelenM, et al.The relationship between gamma-glutamyl transferase levels and the clinical outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis. 2013;24:272–8.
22.
KimJGChangKChooEHLeeJMSeungKB. Serum gamma-glutamyl transferase is a predictor of mortality in patients with acute myocardial infarction. Medicine. 2018;97:e11393.
23.
WangLZhouYJCongHLHuYCZhangJXZhangYY. Association between serum gamma-glutamyl transferase and long-term mortality in elderly patients with coronary artery disease undergoing percutaneous coronary intervention. Chin Circ J. 2018;33:864–8.
24.
NdrepepaGHoldenriederSCasseseS, et al.A comparison of gamma-glutamyl transferase and alkaline phosphatase as prognostic markers in patients with coronary heart disease. Nutr Metab Cardiovasc Dis. 2018;28:64–70.
25.
NdrepepaGBraunSCasseseS, et al.Relation of gamma-glutamyl transferase to cardiovascular events in patients with acute coronary syndromes. Am J Cardiol. 2016;117:1427–32.
26.
ÇağlıKBaşarFNTokDTurakOBaşarÖ. How to interpret liver function tests in heart failure patients?Turk J Gastroenterol. 2015;26:197–203.
27.
ParissisJTFarmakisDAndreoliC, et al.Cardio-reno-hepatic interactions in acute heart failure: the role of γ-glutamyl transferase. Int J Cardiol. 2014;173:556–7.
28.
DoganAIcliAAksoyF, et al.Gamma-glutamyltransferase in acute coronary syndrome patients without ST elevation and its association with stenotic lesion and cardiac events. Coron Artery Dis. 2012;23:39–44.
29.
UlusTYildirirASadeLE, et al.Serum gamma-glutamyl transferase activity: new high-risk criteria in acute coronary syndrome patients?Coron Artery Dis. 2008;19:489–95.
30.
LeeDHBlomhoffRJacobsDRJr. Is serum gamma glutamyltransferase a marker of oxidative stress?Free Radic Res. 2004;38:535–9.
31.
UcarHGurMGozukaraMY, et al.Gamma glutamyl transferase activity is independently associated with oxidative stress rather than SYNTAX score. Scand J Clin Lab Invest. 2015;75:7–12.
32.
VerrijkenAFrancqueSMertensITalloenMPeifferFVan GaalL. Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients. Int J Obes (Lond). 2010;34:899–907.
33.
ShinJYChangSJShinYGSeoKSChungCH. Elevated serum gamma-glutamyltransferase levels are independently associated with insulin resistance in non-diabetic subjects. Diabetes Res Clin Pract. 2009;84:152–157.
34.
MatshaTEMachariaMYakoYYErasmusRTHassanMSKengneAP. Gamma-glutamyltransferase, insulin resistance and cardiometabolic risk profile in a middle-aged African population. Eur J Prev Cardiol. 2014;21:1541–8.
35.
KovalicAJSatapathySK. The role of nonalcoholic fatty liver disease on cardiovascular manifestations and outcomes. Clin Liver Dis. 2018;22:141–74.
36.
ZhangXLiJZhengSLuoQZhouCWangC. Fasting insulin, insulin resistance, and risk of cardiovascular or all-cause mortality in non-diabetic adults: a meta-analysis. Biosci Rep. 2017;37:BSR20170947.
37.
UlusTYildirirADemirtasS, et al.Serum gamma-glutamyl transferase activity: a new marker for stent restenosis?Atherosclerosis. 2007;195:348–53.
38.
DemirtasKYaylaCSadeLE, et al.Platelet membrane gamma-glutamyl transferase-specific activity and the clinical course of acute coronary syndrome. Angiology. 2019;70:166–73.
39.
LauJIoannidisJPTerrinNSchmidCHOlkinI. The case of the misleading funnel plot. BMJ. 2006;333:597–600.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
